Stock Financial Ratios

BIOC / Biocept, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)20.72
Enterprise Value ($M)32.94
Book Value ($M)0.66
Book Value / Share0.07
Price / Book5.07
NCAV ($M)3.18
NCAV / Share0.33
Price / NCAV17.80
Income Statement (mra) ($M)
Net Income-18.40
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio1.19
Current Ratio1.31
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-27.93
Return on Assets (ROA)-2.43
Return on Equity (ROE)-27.93
Identifiers and Descriptors
Central Index Key (CIK)1044378
Industry Groups
SIC 8071 - Medical Laboratories
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)30.26
Scoring Models
Piotroski F Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Liabilities Per Share0.74
Long Term Debt Per Share0.00
Retained Earnings Per Share-19.79
Treasury Stock Per Share0.00
Cash Per Share0.00
Accounts Payable Per Share0.00
Debt Per Share0.00
Equity Per Share0.42
Assets Other Non Current Per Share0.00
Property Plant And Equipment Net Per Share0.30
Liabilities Current Per Share0.61
Intangibles Per Share0.00
Goodwill Per Share0.00
Accounts Receivable Per Share0.12
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Liabilities And Stock Equity Per Share1.16
Inventory Raw Materials Per Share0.00
Cash And Equivalents Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Additional Paid In Capital Per Share20.21
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Assets Current Per Share0.86
Assets Per Share1.16
Inventory Per Share0.08
Property Plant And Equipment Per Share0.30
Minority Interest Per Share0.00
Accumulated Depreciation And Depletion Per Share0.44
Property Plant And Equipment Gross Per Share0.74

Stock Research Report

Biocept is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” its current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic mutations that may qualify a subset of cancer patients for targeted therapy. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. Biocept assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging.

Biocept current assays and planned future assays focus on key solid tumor indications utilizing its Target-Selectors liquid biopsy technology platform for the biomarker anal...

Click for full article

Related News Stories

BRIEF-Biocept files for offering $10 mln of shares of co's common stock and warrants

2017-11-17 reuters
* Biocept Inc files for offering $10 million of shares of co’s common stock and warrants - SEC Filing (17-7)

Biocept's (BIOC) CEO Michael Nall on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Biocept 2017 Third Quarter Conference Call. (17-1)

Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board

2017-10-11 prnewswire
SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that Fred R. Hirsch, M.D., Ph.D. has joined its Clinical Advisory Board.  Dr. Hirsch is Professor of Medicine and Pathology at the University of Colorado Cancer Center. (32-1)

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

2017-10-03 prnewswire
MLS to market Biocept's proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future (32-2)

5 Medtech Stocks to Steer Clear of Amid Political Chaos

2017-09-19 zacks
Since the change in political power in the United States, it has been quite a tumultuous phase for MedTech. Things started getting dramatic since President Trump started forging ahead with his plans to repeal Obamacare. After a series of futile attempts, the Republicans resorted to a “skinny repeal” of Obamacare which failed as well. (35-2)

CUSIP: 09072V105